Use of Chemical Indicators in Light Exposure Validation
Available from Pharma SOP:
Click to read the full article.
Stability Testing Types
Oxidative Degradation in Biopharmaceuticals: Risks and Mitigation
Available from Pharma SOP:
Click to read the full article.
Product-Specific Stability Profiles: A Long-Term Perspective
A product-specific stability profile is a tailored representation of a drug’s behavior over time under various storage conditions. It captures the trends of critical quality attributes (CQAs), degradation kinetics, and environmental sensitivities specific to that formulation.
Click to read the full article.
Risk Mitigation Strategies for Cold Chain Excursion in Injectables
Available from Pharma SOP:
Click to read the full article.
Photo-induced Impurity Profiling Techniques
Available from Pharma SOP:
Click to read the full article.
Designing Stability Protocols: Duration and Pull Point Strategy
A stability protocol is a predefined plan outlining how a drug product or substance will be tested over time under specified environmental conditions. It includes the test parameters, time points (pulls), storage conditions, and acceptance criteria for each study type — real-time, accelerated, and intermediate.
Click to read the full article.
Comparative Analysis: Forced Oxidation vs Photostability Testing
Available from Pharma SOP:
Click to read the full article.
Impact of Light Intensity and Wavelength on Degradation Kinetics
Available from Pharma SOP:
Click to read the full article.
Evaluating Failed Batches in Accelerated Stability Studies
A batch is considered to have failed accelerated stability testing if one or more critical quality attributes fall outside the predefined acceptance criteria established in the stability protocol and aligned with regulatory specifications.
Click to read the full article.
Regulatory Justifications for Omission of Intermediate Condition Studies
As outlined in ICH Q1A(R2), intermediate testing is generally conducted:
Click to read the full article.